Division of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, 2475 North Bank Rd., McKinleyville, CA, 95519, USA.
University of Oregon, Eugene, USA.
J Gen Intern Med. 2018 Dec;33(12):2106-2112. doi: 10.1007/s11606-018-4657-6. Epub 2018 Oct 5.
Programs to improve quality of care and lower costs for the highest utilizers of health services are proliferating, yet such programs have difficulty demonstrating cost savings.
In this study, we explore the degree to which changes in Patient Activation Measure (PAM) levels predict health care costs among high-risk patients.
De-identified claims, demographic data, and serial PAM scores were analyzed on 2155 patients from multiple medical groups engaged in an existing Center for Medicare and Medicaid Innovation-funded intervention over 3 years designed to activate and improve care coordination for high-risk patients.
In this prospective cohort study, four levels of PAM (from low to high) were used as the main predictor variable. We fit mixed linear models for log of allowed charges in follow-up periods in relation to change in PAM, controlling for baseline PAM, baseline costs, age, sex, income, and baseline risk score.
Total allowed charges were derived from claims data for the cohort. PAM scores were from a separate database managed by the local practices.
A single PAM level increase was associated with 8.3% lower follow-up costs (95% confidence interval 2.5-13.2%).
These findings contribute to a growing evidence base that the change in PAM score could serve as an early signal indicating the impact of interventions designed for high-cost, high-needs patients.
旨在提高医疗服务最高使用者的医疗质量并降低成本的项目正在激增,但此类项目难以证明节省成本的效果。
在这项研究中,我们探讨了患者激活量表(PAM)水平变化在多大程度上可以预测高风险患者的医疗保健费用。
分析了来自多个医疗集团的 2155 名患者的匿名索赔、人口统计数据和连续 PAM 评分,这些患者参与了一项现有的联邦医疗保险和医疗补助服务中心(CMS)创新基金资助的干预措施,该措施旨在激活和改善高风险患者的护理协调。
在这项前瞻性队列研究中,我们将 PAM 的四个级别(从低到高)用作主要预测变量。我们拟合了混合线性模型,以研究随访期间的对数允许费用与 PAM 变化之间的关系,同时控制了基线 PAM、基线费用、年龄、性别、收入和基线风险评分。
总允许费用来自队列的索赔数据,PAM 评分则来自当地实践管理的单独数据库。
PAM 水平单一等级的提高与随访成本降低 8.3%(95%置信区间 2.5-13.2%)相关。
这些发现为日益增长的证据基础做出了贡献,即 PAM 评分的变化可以作为一种早期信号,表明针对高成本、高需求患者设计的干预措施的效果。